FY2026 Earnings Forecast for WVE Issued By Cantor Fitzgerald

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Analysts at Cantor Fitzgerald boosted their FY2026 EPS estimates for shares of WAVE Life Sciences in a research note issued to investors on Tuesday, November 11th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will post earnings of ($1.26) per share for the year, up from their prior forecast of ($1.29). Cantor Fitzgerald has a “Overweight” rating and a $12.00 price objective on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The firm had revenue of $7.61 million for the quarter, compared to analyst estimates of $9.85 million.

Other research analysts have also recently issued research reports about the stock. Leerink Partners set a $26.00 target price on shares of WAVE Life Sciences in a research note on Wednesday, September 3rd. Wedbush lifted their price target on WAVE Life Sciences from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of WAVE Life Sciences in a research report on Wednesday, September 3rd. Citigroup started coverage on shares of WAVE Life Sciences in a research report on Wednesday, July 16th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Oppenheimer began coverage on shares of WAVE Life Sciences in a report on Monday, July 28th. They issued an “outperform” rating and a $24.00 price target for the company. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.73.

WAVE Life Sciences Stock Down 2.1%

WAVE Life Sciences stock traded down $0.15 during trading hours on Thursday, hitting $6.80. The stock had a trading volume of 941,424 shares, compared to its average volume of 1,696,720. WAVE Life Sciences has a fifty-two week low of $5.28 and a fifty-two week high of $16.38. The company has a market cap of $1.08 billion, a PE ratio of -7.60 and a beta of -1.44. The company has a 50-day moving average of $7.46 and a two-hundred day moving average of $7.56.

Institutional Investors Weigh In On WAVE Life Sciences

A number of institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of WAVE Life Sciences by 1,441.6% during the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after purchasing an additional 9,284 shares during the period. Inceptionr LLC raised its stake in WAVE Life Sciences by 96.6% in the 3rd quarter. Inceptionr LLC now owns 34,643 shares of the company’s stock worth $254,000 after purchasing an additional 17,026 shares in the last quarter. Knott David M Jr grew its position in shares of WAVE Life Sciences by 125.0% during the 3rd quarter. Knott David M Jr now owns 90,000 shares of the company’s stock worth $659,000 after purchasing an additional 50,000 shares in the last quarter. Cresset Asset Management LLC bought a new position in shares of WAVE Life Sciences during the third quarter worth approximately $134,000. Finally, Rafferty Asset Management LLC raised its position in shares of WAVE Life Sciences by 23.3% in the third quarter. Rafferty Asset Management LLC now owns 16,621 shares of the company’s stock valued at $122,000 after buying an additional 3,138 shares in the last quarter. Institutional investors own 89.73% of the company’s stock.

Insider Activity

In related news, CEO Paul Bolno sold 217,351 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $10.10, for a total value of $2,195,245.10. Following the completion of the transaction, the chief executive officer owned 121,000 shares of the company’s stock, valued at approximately $1,222,100. This trade represents a 64.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gregory L. Verdine sold 10,000 shares of WAVE Life Sciences stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $10.00, for a total value of $100,000.00. Following the completion of the sale, the director directly owned 285,217 shares in the company, valued at approximately $2,852,170. This represents a 3.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 23.98% of the company’s stock.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.